Devices Regenerative Medicine Cardiology Personnel

 News Release - January 6, 2011

BioCardia elects Industry Veteran, Jay M. Moyes, to Board of Directors

San Carlos, California, January 6, 2011 -–(Healthcare Sales & Marketing Network)-- BioCardia, Inc., a cardiovascular regenerative medicine company focused on catheter delivery of autologous cells to treat heart failure, announced today that it has elected Jay M. Moyes, a 30-year veteran of the finance and biotechnology industries, to its board of directors.

Most recently, Moyes served as vice president of finance and CFO at XDX, a privately held molecular diagnostics company. Previously he served in the same role as CFO at Myriad Genetics, a publicly traded molecular diagnostics and therapeutic development company. Prior to that, Moyes served as CFO of Genmark, an agricultural biotechnology company, and as a CPA with the international public accounting firm of KPMG. He received his BA in economics from Weber State University and his MBA from the University of Utah. He serves as a board member at Osiris Therapeutics, a leader in cardiac stem cell therapy.

“I have worked with Jay in past companies and respect his ideas and approach on how to make valuable products, build solid teams, and grow a business that will become both a leader in the field and a positive force in its community.” said Peter Altman, president and chief executive officer of BioCardia, “It will be an honor to work with him in the years ahead.”

About BioCardia, Inc.

BioCardia, Inc. (San Carlos, Calif.) was incorporated in 2002 to design, develop, manufacture, and market innovative devices to enable percutaneous delivery of biologics to treat cardiovascular disease. The company's initial products are intended to provide a new therapeutic option for patients with heart failure and chronic myocardial ischemia. For more information about BioCardia, Inc., visit http://www.BioCardia.com .

Source: BioCardia

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.